PRICE T ROWE ASSOCIATES INC /MD/ - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$59,895
+1.9%
1,567,911
-3.8%
0.01%
+12.5%
Q2 2023$58,792
-5.7%
1,629,901
-0.2%
0.01%
-11.1%
Q1 2023$62,372
-33.1%
1,633,184
-0.3%
0.01%
-40.0%
Q4 2022$93,199
-99.9%
1,637,959
+1.4%
0.02%
+50.0%
Q3 2022$63,859,000
-7.2%
1,615,020
+3.3%
0.01%
+11.1%
Q2 2022$68,788,000
+10.2%
1,563,357
-0.1%
0.01%
+50.0%
Q1 2022$62,422,000
-0.1%
1,565,247
+0.7%
0.01%0.0%
Q4 2021$62,508,000
+1.4%
1,554,544
+2.6%
0.01%0.0%
Q3 2021$61,629,000
-10.9%
1,514,968
-0.5%
0.01%0.0%
Q2 2021$69,155,000
+9.6%
1,522,909
+0.6%
0.01%0.0%
Q1 2021$63,081,000
+18.5%
1,513,095
+21.4%
0.01%
+20.0%
Q4 2020$53,248,000
+3101.9%
1,246,734
+1870.2%
0.01%
Q3 2020$1,663,000
-84.7%
63,278
-84.4%
0.00%
-100.0%
Q2 2020$10,888,000
+655.1%
406,130
+406.6%
0.00%
Q1 2020$1,442,000
+13.5%
80,175
+11.9%
0.00%
Q4 2019$1,270,000
+24.1%
71,630
+8.6%
0.00%
Q3 2019$1,023,000
-8.8%
65,953
+1.0%
0.00%
Q2 2019$1,122,000
+17.6%
65,290
+10.1%
0.00%
Q1 2019$954,000
+10.8%
59,285
+0.7%
0.00%
Q4 2018$861,000
-19.2%
58,885
+0.4%
0.00%
Q3 2018$1,066,000
+6.7%
58,663
-1.0%
0.00%
Q2 2018$999,000
+11.7%
59,226
+29.8%
0.00%
Q1 2018$894,000
-2.7%
45,645
+0.6%
0.00%
Q4 2017$919,000
-3.0%
45,378
-16.7%
0.00%
Q3 2017$947,000
+66.7%
54,508
+23.0%
0.00%
Q2 2017$568,000
-1.0%
44,308
+0.0%
0.00%
Q1 2017$574,000
+14.1%
44,300
-13.0%
0.00%
Q4 2016$503,000
-32.3%
50,900
-17.2%
0.00%
Q3 2016$743,000
+71.6%
61,500
+22.5%
0.00%
Q2 2016$433,000
+8.0%
50,200
+18.7%
0.00%
Q1 2016$401,000
-45.3%
42,3000.0%0.00%
Q4 2015$733,000
+27.3%
42,300
-1.4%
0.00%
Q3 2015$576,000
-34.4%
42,900
+10.3%
0.00%
Q2 2015$878,000
+114.1%
38,900
+35.5%
0.00%
Q1 2015$410,000
+43.4%
28,700
-3.0%
0.00%
Q4 2014$286,000
+6.3%
29,6000.0%0.00%
Q3 2014$269,000
-7.9%
29,6000.0%0.00%
Q2 2014$292,000
-62.1%
29,600
-51.2%
0.00%
Q1 2014$771,000
-63.9%
60,700
-57.4%
0.00%
Q4 2013$2,134,000
+151.4%
142,400
+85.2%
0.00%
Q3 2013$849,000
-22.7%
76,900
-44.4%
0.00%
Q2 2013$1,098,000138,2000.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders